Archive for April, 2007
Migraine pipeline.
Alexa (pipeline)
Biofrontera (pipeline)
Faust Pharma (pipeline)
Glide Pharma (pipeline)
Map Pharmaceuticals (pipeline)
Mystic Pharmaceuticals (pipeline)
Meditor (pipeline)
Nektar (pipeline)
NovaDel (pipeline)
Nupathe (pipeline)
Physica Pharma (pipeline)
Pozen (pipeline)
TorreyPines Therapeutics (pipeline)
Vernalis (pipeline)
More cost-cutting measures: Acambis/Avant.
Both Acambis and Avant Immunotherapeutics have begun plans to restructure…
VaxGen did this not too long ago; let’s hope Vical doesn’t do likewise.
Sigh .
Genaera realigns itself to focus on obesity and asthma.
Genaera announced earlier that it has realigned its business model and resources to focus on its obesity and asthma businesses.
Blogged with Flock
Brain dump of insomnia-pipeline companies…
Evotec
Neurocrine
Vanda
Lundbeck
Arena
Neurogen
Pherin
NovaDel
Astellas
Takeda
Acadia
Memory Pharma
Somaxon
Grazax: a new allergy treatment.
Looking forward to Grazax, an oral-based tablet/vaccine for Ragweed, launching in the U.S. hopefully in the next couple of years.
Read Full Post | Make a Comment ( None so far )The Immune Response Corporation canceling its HIV clinical trials.
Bad, bad news for the therapeutic HIV pipeline: The Immune Response Corporation, which had been developing Remune as a therapy for HIV/AIDS, has announced it has canceled its HIV clinical trials.
The company also announced it will rebrand itself to Orchestra Therapeutics in light of the changes.
Blogged with Flock
Curalogic
Curalogic has a new ragweed/allergy candidate. Yay!
Read Full Post | Make a Comment ( None so far )Epeius Biotech
Epeius Biotech is, according to them, the “world’s first tumor-targeted gene delivery” company. Its Rexin-G product looks interesting.
Blogged with Flock
Dendreon’s Provenge cancer vaccine soon to be approved?
Dendreon’s therapeutic (not preventative) cancer vaccine “Provenge” has been reviewed by the FDA, and is likely to be approved soon.
Read Full Post | Make a Comment ( 2 so far )
